Form 13G’s must be filed with the SEC upon any investor or entity amassing at least 5% of a company’s outstanding shares, or alternatively, an investment falling beneath the 5% ownership threshold. Investors should closely monitor this filing activity, as it represents the trading activity of some of the company’s biggest supporters, who have doubtlessly done an immense amount of research on the company and its sector and have a good understanding of its value and potential. Below we have embedded just such a filing, issued by James Flynn‘s Deerfield Management on Editas Medicine Inc (NASDAQ:EDIT), which had its IPO earlier this month and which has 5.07% of its shares owned by Deerfield now.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt HIF, | 0 | 854,700 | 0 | 854,700 | 854,700 | 2.39% |
| Deerfield Management Company, | 0 | 1,809,400 | 0 | 1,809,400 | 1,809,400 | 5.07% |
| Deerfield Mgmt III, | 0 | 954,700 | 0 | 954,700 | 954,700 | 2.67% |
| Deerfield Healthcare Innovations Fund, | 0 | 854,700 | 0 | 854,700 | 854,700 | 2.39% |
Follow James E. Flynn's Deerfield Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 13 SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *
Editas Medicine, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
28106W103
(CUSIP Number)
February 2, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
(Page 1 of 11 Pages)
———-
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 2 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt HIF, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 854,700 (1) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 854,700 (1) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 854,700 (1) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.39% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(1) Comprised of common stock held by Deerfield Healthcare Innovations Fund, L.P., of which Deerfield Mgmt HIF, L.P. is the general partner.
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 3 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Management Company, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 1,809,400 (2) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 1,809,400 (2) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,809,400 (2) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.07% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(2) Comprised of common stock held by Deerfield Private Design Fund III, L.P. and Deerfield Healthcare Innovations Fund, L.P., of which Deerfield Management Company, L.P. is the investment advisor.
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 4 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt III, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 954,700 (3) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 954,700 (3) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 954,700 (3) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.67% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 5 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Healthcare Innovations Fund, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 854,700 | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 854,700 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 854,700 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.39% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 13 SEC Filing
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 8 of 11 |
| Item 1(a). | Name of Issuer: | |
| Editas Medicine, Inc. | ||
| Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
| 300 Third Street, First Floor Cambridge, MA 02142 | ||
| Item 2(a). | Name of Person Filing: | |
| James E. Flynn, Deerfield Mgmt HIF, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P. | ||
| Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
| James E. Flynn, Deerfield Mgmt HIF, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 | ||
| Item 2(c). | Citizenship: | |
| Deerfield Mgmt HIF, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Healthcare Innovations Fund, L.P. – Delaware limited partnerships; James E. Flynn – United States citizen | ||
| Item 2(d). | Title of Class of Securities: | |
| Common Stock, $0.0001 par value per share | ||
| Item 2(e). | CUSIP Number: | |
| 28106W103 | ||
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| (a) | o | Broker or dealer registered under Section 15 of the Exchange Act. | |
| (b) | o | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
| (c) | o | Insurance company as defined in Section 3(a)(19) of the Exchange Act. | |
| (d) | o | Investment company registered under Section 8 of the Investment Company Act. |
| (e) | o | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | o | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); |
| (g) | o | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); |
| (h) | o | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 9 of 11 |
| (i) | o | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; |
| (j) | o | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); |
| k) | o | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________
| Item 4. | Ownership. |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
| (a) | Amount beneficially owned**: | ||
| Deerfield Mgmt HIF, L.P. – 854,700 shares Deerfield Mgmt III, L.P. – 954,700 shares Deerfield Management Company, L.P. – 1,809,400 shares Deerfield Healthcare Innovations Fund, L.P. – 854,700 shares Deerfield Private Design Fund III, L.P. – 954,700 shares James E. Flynn – 1,809,400 shares | |||
| (b) | Percent of class**: | ||
| Deerfield Mgmt HIF, L.P. – 2.39% Deerfield Mgmt III, L.P. – 2.67% Deerfield Management Company, L.P. – 5.07% Deerfield Healthcare Innovations Fund, L.P. – 2.39% Deerfield Private Design Fund III, L.P. – 2.67% James E. Flynn – 5.07% |
| (c) | Number of shares as to which such person has**: | ||||
| (i) | Sole power to vote or to direct the vote: | All Reporting Persons – 0 | |||
| (ii) | Shared power to vote or to direct the vote: | Deerfield Mgmt HIF, L.P. – 854,700 shares Deerfield Mgmt III, L.P. – 954,700 shares Deerfield Management Company, L.P. – 1,809,400 shares Deerfield Healthcare Innovations Fund, L.P. – 854,700 shares Deerfield Private Design Fund III, L.P. – 954,700 shares James E. Flynn – 1,809,400 shares | |||
| (iii) | Sole power to dispose or to direct the disposition of: | All Reporting Persons – 0 | |||
| (iv) | Shared power to vote or to direct the vote: | Deerfield Mgmt HIF, L.P. – 854,700 shares Deerfield Mgmt III, L.P. – 954,700 shares Deerfield Management Company, L.P. – 1,809,400 shares Deerfield Healthcare Innovations Fund, L.P. – 854,700 shares Deerfield Private Design Fund III, L.P. – 954,700 shares James E. Flynn – 1,809,400 shares |
**See footnotes on cover pages which are incorporated by reference herein.
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 10 of 11 |
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following o.
| | |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
| | N/A |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
| | N/A |
| Item 8. | Identification and Classification of Members of the Group. |
If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.
| | See Exhibit B |
| Item 9. | Notice of Dissolution of Group. |
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
| | N/A |
| Item 10. | Certifications. |
“By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.”
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 13 SEC Filing
| CUSIP No. | 28106W103 | 13G | Page 11 of 11 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DEERFIELD MGMT HIF, L.P.
By: J.E. Flynn Capital HIF, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD HEALTHCARE INNOVATIONS FUND, L.P.
By: Deerfield Mgmt HIF, L.P., General Partner
By: J.E. Flynn Capital HIF, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Date: February 8, 2016
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 13 SEC Filing
Exhibit List
Exhibit A. Joint Filing Agreement.
Exhibit B. Item 8 Statement.
Exhibit C. Power of Attorney (1).
(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P., Deerfield PDI Financing, L.P., Deerfield PDI Financing II, L.P., Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield International Master Fund, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Breaking Stick Holdings, LLC, Deerfield Private Design Fund III, L.P. and James E. Flynn.
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 12 of 13 SEC Filing
Exhibit A
Joint Filing Agreement
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock, $0.0001 par value per share of Editas Medicine, Inc. shall be filed on behalf of the undersigned.
DEERFIELD MGMT HIF, L.P.
By: J.E. Flynn Capital HIF, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD HEALTHCARE INNOVATIONS FUND, L.P.
By: Deerfield Mgmt HIF, L.P., General Partner
By: J.E. Flynn Capital HIF, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 13 of 13 SEC Filing
Exhibit B
Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
